Hospital News
Return to Prevention Programs Overview
More on Prevention Programs
- Largest U.S. Hepatitis C Trial Provides Insight Into Optimizing Treatment for Patients
- $4 Million Gift Helps Create New Center for Inflammatory Bowel Disease at NewYork-Presbyterian/Weill Cornell
- Baby Receives Five Transplanted Organs at Morgan Stanley Children's Hospital
- Children's Hospital Appoints Foremost Authority on Treatment of Pediatric Liver and Bowel Disease
- COX-2 Inhibitor May Boost Cancer Treatment, NewYork Weill Cornell Study Shows
- Decades-Long Study Will Help Improve Surgery for Crohn's Disease
- Diabetes Surgery Program Opens at NewYork-Presbyterian/Weill Cornell
- Dr. Louis Aronne Named President of the North American Association for the Study of Obesity (NAASO)
- Dr. Timothy Wang Named Chief of Gastroenterology at NewYork-Presbyterian/Columbia and Silberberg Professor of Medicine at Columbia University College of Physicians and Surgeons
- Dr. William B. Inabnet Named Chief of Endocrine Surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center
- Duodenal Switch May Be More Effective Than Gastric Bypass, NewYork-Presbyterian/Weill Cornell Study Finds
- Eltrombopag Effective for Hepatitis C Patients With Low Blood-Platelet Counts
- Futuristic Surgical Suites Open at NewYork-Presbyterian
- Gall Bladder Removed Vaginally Using Endoscope With Minimal External Incisions
- Gallbladder Removed Without External Incisions
- In Largest U.S. Hepatitis C Trial, NewYork-Presbyterian/Weill Cornell Researchers Determine Weight-Based Dosing Is Key to Optimal Treatment
- Largest Hepatitis C Trial in U.S. Patients Shows Weight-Based REBETOL in Combination with PEG-INTRON Increases Sustained Response, Lowers Relapse
- New Combined Laparoscopy and Colonoscopy Procedure May Avoid Need for Major Surgery
- New Comprehensive Gastrointestinal Health Center To Be Established at NewYork-Presbyterian Weill Cornell
- NewYork-Presbyterian Receives Highest Accreditation for Bariatric Surgery
- NYC Area's First Patient Receives New Incision-Free Weight-Loss Surgery at NewYork-Presbyterian/Columbia
- Responding to Obesity Epidemic, New Adolescent Bariatric Surgery Center Opens at Morgan Stanley Children's Hospital of NewYork-Presbyterian
- Review Outlines Risks and Benefits of Body Contouring for Massive Weight Loss After Bariatric Surgery
- Small, Open-Label Study Shows Potential Use of Novel Antibiotic Rifaximin for Crohn's Disease
- Study Shows Weight-Based REBETOL Dosing in Combination with PEG-INTRON Significantly Improves Viral Clearance in African-American Patients with Most-Difficult-To-Treat Form of Hepatitis C
- Surgeons Who Helped Pioneer Revolutionary Technique Present International Course on NOTES Surgery
- Type 2 Diabetes May Be Caused by Intestinal Dysfunction
- Want a Healthy Colon? Eat a Rainbow!
- Weill Cornell Scientists Identify Mechanism Governing Immune System Suppression
Health Library
Return to Prevention Programs Overview
More on Prevention Programs
- Alcoholic Hepatitis
- Alcohol-Induced Liver Disease
- Anal Abscess and Fistula
- Anal Cancer
- Appendicitis
- Autoimmune Hepatitis
- Barium X-Rays (Upper and Lower GI)
- Barrett's Esophagus
- Biliary Cirrhosis / Bile Duct Cancer
- Biliary System
- Cancer, Colorectal
- Celiac Disease
- Cholangitis
- Cholecystitis
- Chronic Liver Disease / Cirrhosis
- Common Liver Function Tests
- Constipation
- Crohn's Disease
- Diarrhea
- Digestive Disorder Diagnostic Procedures
- Digestive System and Medications
- Digestive System Overview
- Diverticular Disease
- Esophageal Cancer
- Gallstones
- Gas in the Digestive Tract
- Gastritis
- Gastroesophageal Reflux Disease (GERD) / Heartburn
- Gastrointestinal Cancers
- Gastroparesis
- Giardiasis
- Helicobacter Pylori
- Hemolytic Uremic Syndrome
- Hemorrhoids
- Hepatitis, Drug-Induced
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Indigestion
- Irritable Bowel Syndrome (IBS)
- Lactose Intolerance
- Lactose Intolerance: Diet
- Liver, Biliary, and Pancreatic Disease: Diagnosis
- Liver Anatomy and Function
- Liver Defects, Congenital
- Liver Disease: Common Characteristics
- Liver Disease: Statistics
- Liver Disorders
- Liver Transplant Surgery
- Liver Tumors
- Pancreatitis
- Peritonitis
- Pseudocysts of the Pancreas
- Salmonella Infections
- Stomach and Duodenal Ulcers (Peptic Ulcers)
- Stomach Cancer
- Traveler's Diarrhea
- Ulcerative Colitis
- Viral Hepatitis
Clinical Services
Return to Prevention Programs Overview
More on Prevention Programs
- Advanced Diagnostics
- Anorectal Disease
- Colon and Rectal Surgery
- Colorectal Disease
- Diabetes and Endocrinology
- Gastroenterology and Hepatology (Digestive Diseases)
- General Surgery
- Groundbreaking Therapeutics
- Liver Cancer
- Liver Disease
- Minimal Access Surgery Center
- Pancreatic and Biliary Cancer
- Preventive Medicine and Nutrition
- Stomach Cancer
- Stomach Disease
Prevention Programs
The development of new clinical approaches and strategies for prevention are the focus of concerted research efforts in digestive diseases at NewYork-Presbyterian Hospital, Columbia University College of Physicians & Surgeons, and Weill Medical College of Cornell University. In the area of cancer screening and control, scientific endeavors are guided by world-renowned researchers in the field of Cox-2 inhibitors in GI cancer and leading authorities on cancer genetics, early detection and screening protocols.
Selective Cox-2 inhibitors are the focus of two major chemoprevention trials conducted at the Hospital's two academic medical centers. One trial seeks to prevent esophageal cancer by reducing existing benign lesions in patients with Barrett's esophagus. A second trial looks at preventing the recurrence of polyps, a widely recognized precursor of colorectal cancer, in patients who have had a colorectal adenoma removed. In addition, research is exploring natural substances, including derivatives and extracts from green tea, that may play a role in chemoprevention; nutro-genomics-understanding how nutrients can interact with the human genome to alter the expression of genes implicated in disease using Cox 2 as a prototype; and identification of novel therapeutic targets of non-steroidal anti-inflammatory drugs in the prevention of tumors.
The Hospital's cancer prevention programs provide expertise in colon cancer genetics, screening, prevention, and early detection, and offer recommendations for genetic counseling and testing when appropriate.
Contact
- Digestive and Liver Diseases, NewYork-Presbyterian/Columbia
-
Directions
(212) 305-8156
- Gastroenterology and Hepatology, NewYork-Presbyterian/Weill Cornell
-
Directions
(212) 746-4400
